Stability-indicating study of the anti-Alzheimer's drug galantamine hydrobromide

Journal of Pharmaceutical and Biomedical Analysis

Volumn 55, Issue 1, 2011, Pages 85-92

  Marques, Lygia Azevedo ^a   Maada, Ismail ^a   de Kanter, Frans J J ^a   Lingeman, Henk ^a   Irth, Hubertus ^a   Niessen, Wilfried M A ^a   Giera, Martin ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Acetylcholinesterase; Degradation; Galantamine hydrobromide; RP LC

Indexed keywords

GALANTAMINE;

ACCURACY; ACIDITY; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DEGRADATION KINETICS; DEHYDRATION; DRUG DEGRADATION; DRUG DETERMINATION; DRUG STABILITY; EPIMERIZATION; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE; OXIDATION; PHOTOLYSIS; PRIORITY JOURNAL; REVERSED PHASE LIQUID CHROMATOGRAPHY; SENSITIVITY AND SPECIFICITY; TEMPERATURE;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; CHOLINESTERASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; GALANTAMINE; HOT TEMPERATURE; HYDROGEN-ION CONCENTRATION; KINETICS; LIGHT; MAGNETIC RESONANCE SPECTROSCOPY; OXIDATION-REDUCTION; PHOTOLYSIS; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STEREOISOMERISM; TANDEM MASS SPECTROMETRY; TECHNOLOGY, PHARMACEUTICAL;

EID: 79951757766     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2011.01.022     Document Type: Article

References (24)

1. Hoffmann M., Hock C. Int. Encyclopedia Soc. Behav. Sci. 2004, 418-423.
2. de Jong C.F., Derks R.J.E., Bruyneel B., Niessen W.M.A., Irth H. High-performance liquid chromatography-mass spectrometry based acetylcholinesterase assay for the screening of inhibitors in natural extracts. J. Chromatogr. A 2006, 1112:303-310.
3. Küenburg B., Czollner L., Fröhlich J., Jordis U. Development of a pilot scale process for the anti-alzheimer drug (-)-galanthamine using large-scale phenolic oxidative coupling and crystallization-induced chiral conversion. Org. Process. Res. Dev. 1999, 3:425-431.
4. Leonard A.K., Sileno A.P., MacEvilly C., Foerder C.A., Quay S.C., Costantino H.R. Development of a novel high-concentration galantamine formulation suitable for intranasal delivery. J. Pharm. Sci. 2005, 94:1736-1746.
5. Berkov S., Codina C., Viladomat F., Bastida J. N-Alkylated galanthamine derivatives: potent acetylcholinesterases inhibitors from Leucojum aestivum. Bioorg. Med. Chem. Lett. 2008, 18:2263-2266.
6. European Pharmacopoeia, 7th edition, Monography Galantamine Hydrobromide, Strasbourg, France, 2010.
7. The United States Pharmacopeial Convention, Official Monograph Galantamine, Revision Bulletin 15 December 2008.
8. Visky D., Jimidar I., Van Ael W., Vennekens T., Redlich D., De Smet M. Capillary electrophoresis-mass spectrometry in impurity profiling of pharmaceuticals products. Electrophoresis 2005, 26:1541-1549.
9. Bakshi M., Singh S. Development of validated stability-indicating assay methods-critical review. J. Pharm. Biomed. Anal. 2002, 28:1011-1040.
10. ICH, (Q2R1) validation of analytical procedures: text and methodology, International Conference on Harmonisation, Geneva, November 1996.
11. Marques L.A., Giera M., de Kanter F.J.J., Niessen W.M.A., Lingeman H., Irth H. Photohuperzine A-a new photoisomer of huperzine A: structure elucidation, formation kinetics and activity assessment. J. Pharm. Biomed. Anal. 2010, 52:190-194.
12. European Pharmacopoeia, 7th edition, Monograph Hydrogen Peroxide Solution (3 per cent), Strasbourg, France, 2010.
13. 1H NMR. Phytochem. Anal. 2010, 21:66-72.
14. Jegorov A., Buchta M., Sedmera P., Kuzma M., Havlicek V. Accurate product ion mass spectra of galanthamine derivatives. J. Mass Spectrom. 2006, 41:544-548.
15. Han S.Y., Sweeney J.E., Bachman E.S., Schweiger E.J., Forloni G., Coyle J.T., Davis B.M., Joullié M.M. Chemical and pharmacological characterization of galanthamine, an acetylcholinesterase inhibitor, and its derivatives. A potential application in Alzheimer's disease?. Eur. J. Med. Chem. 1992, 27:673-687.
16. Zhang L.H., Gupta A.K., Cook J.M. Reinvestigation of the mechanism of the acid-catalyzed epimerization of reserpine to isoreserpine. J. Org. Chem. 1989, 54:4708-4712.
17. Kumar S., Rurak D.W., Riggs K.W. Simultaneous determination of diphenhydramine, its N-oxide metabolite and their deuterium-labeled analogues in ovine plasma and urine using liquid chromatography/electrospray tandem mass spectrometry. J. Mass Spectrom. 1998, 33:1171-1181.
18. Maláková J., Nobilis M., Svoboda Z., Lísa M., Holcapek M., Kvetina J., Klimes J., Palicka V. High-performance liquid chromatography method with UV photodiode-array, fluorescence and mass spectrometric detection for simultaneous determination of galantamine and its phase I metabolites in biological samples. J. Chromatogr. B 2007, 853:265-274.
19. Marques L.A., Kool J., Kanter F.J.J., Lingeman H., Niessen W.M.A., Irth H. On-line AChE bioactivity profiling of chemical and biological degradation products of tacrine with parallel high resolution mass spectrometry. J. Pharm. Biomed. Anal. 2010, 53:609-616.
20. Liu D.Q., Hop C.E.C.A. Strategies for characterization of drug metabolites using liquid-chromatography-tandem mass spectrometry in conjunction with chemical derivatization and on-line H/D exchange approaches. J. Pharm. Biomed. Anal. 2005, 37:1-18.
21. Lee T.B.K., Goehring K.E., Ma Z. One-step convertion of galanthamine to lycoraminone: a novel hydride-transfer reaction. J. Org. Chem. 1998, 63:4535-4538.
22. Bickel U., Thomsen T., Fischer J.P., Weber W., Kewitz H. Galanthamine: pharmacokinetics, tissue distribution and cholinesterase inhibition in brain of mice. Neuropharmacology 1991, 30:447-454.
23. Berkov S, Bastida J., Nikolova M., Viladomat F., Codia C. Rapid TLC/GC-MS identification of acetylcholinesterase inhibitors in alkaloid extracts. Phytochem. Anal. 2008, 19:411-419.
24. Thomson T., Bickel U., Fisher J.P., Kewitz H. Stereoselectivity of cholinesterase inhibition by galanthamine and tolerance in humans. Eur. J. Clin. Pharmacol. 1990, 39:603-605.